OBI Business Summary

OBI Pharma, Inc. (4174.TWO) is a clinical-stage biopharmaceutical company specializing in the development of novel cancer therapies, primarily targeting the Globo-series carbohydrate antigens (Globo H, SSEA-4) and advancing a proprietary Antibody-Drug Conjugate (ADC) platform. The company generates revenue through strategic out-licensing agreements, milestone payments, and collaborative research and development fees, with business segments spanning anti-cancer therapeutics, bispecific monoclonal antibodies, botulinum toxin (OBI-858), and CDMO services. Its lead assets include Adagloxad Simolenin (OBI-822) for triple-negative breast cancer and the TROP2-targeted ADC OBI-992. OBI Pharma competes with global oncology players such as Gilead Sciences, Daiichi Sankyo, and Jazz Pharmaceuticals, positioning itself as a niche leader in glycan-targeting immuno-oncology and a premier ADC developer in the Taiwan market. The company is led by CEO Dr. Heidi Wang, a veteran with over 30 years of experience at Bristol Myers Squibb, where she served as Vice President of Global Regulatory Sciences Oncology. The board is chaired by Dr. Kung-Yee Liang, a world-renowned biostatistician and former President of the National Health Research Institutes (NHRI), who succeeded former Chairman Yun Yen in late 2023. OBI Pharma was founded by the late Dr. Michael Chang, a former Merck executive and founder of Optimer Pharmaceuticals, and is significantly backed by the Ruentex Group under billionaire Samuel Yin. Other key leadership figures include Chief Operating Officer Colin Kao and Chief Scientific Officer Dr. Ya-Chi Chen, who oversee a pipeline increasingly focused on next-generation dual-payload ADCs and bispecific antibodies.